Zorevunersen clinical trials
How each study uses zorevunersen is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- zorevunersen
- 1
Studies by the year they started
3 studies that test it; most in 2020 (1)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Stoke Therapeutics, Inc (3)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test zorevunersen, phase 3 first.
- Mar 2027A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet SyndromePhase 3 · Stoke Therapeutics, Inc
Studies
Open first, then newest update. How each study uses zorevunersen is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet SyndromeActive, not recruitingPhase 3Stoke Therapeutics, IncNCT06872125Written as zorevunersen
- An Open-Label Extension Study of STK-001 for Patients With Dravet SyndromeActive, not recruitingPhase 2Stoke Therapeutics, IncNCT04740476Written as zorevunersen (STK-001)
- An Open-Label Study to Investigate the Safety of Single and Multiple Ascending Doses in Children and Adolescents With Dravet SyndromeCompletedPhase 1/2Stoke Therapeutics, IncNCT04442295Written as STK-001 - Single Ascending Doses
Codes
What other systems call zorevunersen · ClinicalTrials.gg INT018084
- UNII (FDA) U4YV46D2DTZOREVUNERSENOne source FDA
- NCI Thesaurus C184885ZorevunersenOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | U4YV46D2DT | ZOREVUNERSEN | One source FDA |
| NCI Thesaurus | C184885 | Zorevunersen | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.